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Intradialysis hypertension is a frustrating complication
among hemodialysis (HD) patients. This study was conducted
to investigate the physiological changes during intradialytic
hypertension. The beat-to-beat continuous heart rate,
hematocrit (Hct) changes during HD, serum levels of nitric
oxide, plasma levels of catecholamine, renin, endothelin
(ET-1), cardiac output (CO), and peripheral vascular resistance
(PVR) were measured before and after HD in patients prone
to develop intradialysis hypertension (n¼ 30) and from age,
sex-matched control HD subjects (n¼ 30). It was found that
the baseline values of Hct, serum levels of nitric oxide,
plasma levels of catecholamine, renin, and ET-1, CO, PVR, and
power index (low frequency/high frequency ratios) of heart
rate variability were not significantly different between the
patients and control subjects. In the hypertension-prone
group, the plasma levels of catecholamine, renin, and the
serial measurements of power index, did not show significant
changes. However, the patients showed a significant
elevation of systemic vascular resistance (56.879.2% vs
17.779.5; Po0.05), ET-1 (510.9743.3 vs 276.7730.1 pg/ml;
Po0.05) and a significant decrease of nitric oxide (NO)/ET-1
balance (0.01870.003 vs 0.03470.005; Po0.05) at the end of
HD compared with the control patients. It was found that the
physiological changes in intradialysis hypertension patients
were characterized by inappropriately increased PVR through
mechanisms that did not involve sympathetic stimulation or
renin activation but might be related with altered NO/ET-1
balance.
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Acute complications such as hypotension, hypertension, and
muscle cramps prevent uremic patients from having a safe
and comfortable hemodialysis (HD) treatment. The patho-
genesis of HD-related hypotension has frequently been
investigated and seems easy to understand; it includes cardiac
performance, integrity of the cardiovascular reflex control,
delayed plasma refilling from the extravascular space, uremic
dysautonomia, activation of cytokines, changes in blood
osmolality, release of neurohumoral mediators, and excessive
ultrafiltration1–6 and so on. However, the mechanisms of
dialysis-related hypertension have not yet been well explored.
Many explanations for the phenomenon of intradialytic
hypertension, including augmented release of renin, activa-
tion of the sympathetic nervous system, and endothelial
dysfunction have been proposed.7–9 None of these possible
explanations, or their inter-relationships, has been studied in
a controlled experimental setting. To investigate the hemo-
dynamic changes and responses of autonomic nervous
function during intradialytic hypertension of HD patients,
the changes of autonomic function of intradialytic hyperten-
sive patients were studied by measuring the heart rate
variability (HRV), which was proposed to be a sensitive and
well-established tool for investigating the autonomic nervous
system during HD.10–11 Plasma levels of epinephrine,
norepinephrine, rennin, and endothelin (ET-1), and serum
levels of nitric oxide (NO) were measured at the beginning
and the end of HD. Echocardiograms were performed to
evaluate the changes of cardiac output (CO) and peripheral
vascular resistance (PVR) before and after HD.
RESULTS
The general characteristics of the groups are shown in
Table 1. Body height, dry weight, body mass index,
ultrafiltration volume, albumin, hematocrit (Hct), duration
of maintenance dialysis, and baseline heart rate were not
significantly different between the groups. However, baseline
mean arterial pressure of group A were significantly different
from those of group B (10573 vs 9573 mm Hg, Po0.05).
The laboratory data before and after HD are shown in
Table 2. Before HD there were no significant differences
among all of the variables. However, significant differences in
the plasma concentrations of norepinephrine and renin
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2006 International Society of Nephrology
Received 9 April 2005; revised 15 October 2005; accepted 18 November
2005; published online 22 February 2006
Correspondence: H-C Fang, Division of Nephrology, Kaohsiung Veterans
General Hospital, 386 Ta-Chung 1st Rd, Kaohsiung, Taiwan 813, ROC.
E-mail: hcfang@isca.vghks.gov.tw
Kidney International (2006) 69, 1833–1838 1833
between groups A and B were found at the end of HD
(204727 vs 363762 pg/ml and 10.672.8 vs 24.977.3 pg/ml,
respectively; Po0.05 for both). When before and after HD
measurements were compared, there were no significant
differences in the plasma concentrations of epinephrine,
norepinephrine, and renin in group A, but the serum levels of
norepinephrine and renin increased significantly at the end of
HD in group B (253747 vs 363762 pg/m and 15.173.1 vs
24.977.3 pg/ml; both Po0.05).
Figure 1a shows the changes in mean arterial blood
pressure of each group. There were significant elevations of
mean arterial blood pressure in group A (at 3 and 4 h after
beginning HD vs baseline; Po0.05), but no significant
changes were seen in group B throughout the whole dialysis
session.
Serial changes of percentage of blood volume (BV) during
HD are depicted in Figure 1b. There were no differences
between the baseline levels of the groups. However, the levels
increased gradually with time. The values of changes of BV in
group B patients were statistically higher than those of group
A during the whole course of HD. As the ultrafiltration rates
of the groups were similar, the lesser changes of percentage of
BV in group A implied a faster refilling of intravascular
volume.
Spectral analysis data of HRV are shown in Figure 1c. The
baseline values of LH/HF ratios of both groups were not
significantly different. The serial measurements of low
frequency/high frequency (LF/HF) ratios rose progressively
and reached significantly higher levels during the 3rd and 4th
hour periods of HD in group B patients (2.170.3 vs 3.170.5
and 3.770.5; both Po0.05). The LF/HF ratios in group A
patients, however, did not change significantly throughout
the whole dialysis session.
The changes of COs and PVRs are displayed in Table 3.
The baseline levels of both of them were not significantly
different between groups. However, at the end of HD the
elevations of PVR were significantly higher in group A
patients than those of group B (56.879.2 vs 17.779.5%;
Po0.05).
The plasma concentrations of nitric oxide (nitra-
teþ nitrite) and ET-1 before and after HD are shown in
Table 4. The predialysis levels of both of them were




Number of patients 30 30 —
Age (years) 53.273.9 54.374.2 NS




Body height (cm) 159.871.6 158.971.7 NS
Body weight (kg) 52.271.6 53.972.0 NS
Body mass index 20.470.4 21.370.6 NS
Ultrafiltration volume (l) 2.170.3 2.370.3 NS
Serum albumin (g/dl) 4.270.1 4.270.1 NS
i-PTH (pg/ml) 189.7756.2 343.77105.7 NS
Baseline Hct (%) 28.571.1 28.870.6 NS
Baseline mean arterial pressure
(mmHg)
10573 9573 o0.05
Baseline pulse rate (min1) 7372 7272 NS
Baseline LF/HF ratio 2.470.4 2.170.3 NS
Abbreviations: LF/HF ratio, ratio of low- and high-frequency power of heart rate
variability; NS, not significant.
All data are presented as mean7s.e.m.




Plasma potassium (mEq/l) 4.470.3 4.470.5 NS
Plasma free calcium (mg/dl) 4.270.1 4.470.1 NS
Plasma epinephrine (pg/ml) 97.1713.5 99.078.5 NS
Plasma norepinephrine (pg/ml) 225743 253747 NS
Plasma renin concentration (pg/ml) 10.873.4 15..173.1 NS
After hemodialysis
Plasma potassium (mEq/l) 3.270.1* 3.370.1* NS
Plasma free calcium (mg/dl) 5.070.1* 5.170.1* NS
Plasma epinephrine (pg/ml) 87.679.8 100.476.8 NS
Plasma norepinephrine (pg/ml) 204727 363762* o0.05
Plasma renin concentration (pg/ml) 10.672.8 24.977.3* o0.05
Abbreviation: NS, not significant.
All data are presented as mean7s.e.m.
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Figure 1 | (a) Changes of mean arterial pressure, (b) changes of
percentage of hematocrit (Hct), and (c) power index (ratio of
low- and high-frequency power of heart rate variability) during
dialysis of hypertension-prone patients and controls. *Po0.05 vs
baseline values of the respective groups. **Po0.05 comparisons
between the groups.
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comparable in the two study groups. The postdialysis NO
levels displayed significantly decreased in both groups, but
showed no significant differences between groups. The
postdialysis ET-1 levels were significantly elevated in group
A as compared with that of group B and predialysis levels.
Although the NO/ET-1 balance was significantly depressed
after HD in both groups, it was significantly less in group A
than that of group B.
DISCUSSION
Although it occurs less frequently than hypotension, the
incidence of intradialysis hypertension has been reported to
be around 8%.12 Some authors have proposed that
disturbances of the renin–angiotension–aldosterone system,
changes of Hct and serum electrolytes levels, or autonomic
dysfunction may contribute to the development of intradia-
lysis hypertension.7 However, the actual physiological
changes during hemodialyis in intradialytic hypertensive
patients still remained unexplored.
During HD there are usually two physical processes
occurring, diffusion and ultrafiltration, which result in a
reduction in circulating plasma volume. To maintain
adequate blood pressure, the usual response is an increase
in CO and PVR. The primary mechanism is the acute
stimulation of the sympathetic nervous system, with an
increase in stroke volume and heart rate, and vasoconstric-
tion with an increase in PVR. These physical changes were
displayed by our control group patients, either shown by the
plasma concentrations of catecholamine and renin, or by the
results of analysis of HRV. However, the changes were not
displayed in the hypertension-prone group patients. In this
study, we found that the hypertension-prone HD patients
had higher predialysis blood pressure, lower reduction of
percentage in BV, almost no change of plasma levels of
catecholamine and renin, as well as power index, but a higher
increase of systemic vascular resistance (SVR). It seemed that
it was the inappropriate elevation of SVR through mechan-
isms not involving sympathetic stimulation or renin activa-
tion that led to intradialytic hypertension. The autonomic
nervous system seemed intact in hypertension-prone HD
patients and showed a protective response to the elevated
blood pressure, including the inhibition of central sympa-
thetic flow through the baroreceptor reflex.13,14 However,
what is the factor (or factors) that provokes the inappropriate
elevation of PVR during HD? More recently, emerging
evidence indicates that endothelial dysfunction may play a
key role in hemodynamic instability during HD.15,16 During
HD, in response to mechanical and hormonal stimuli,
endothelial cells synthesize and release humoral factors,
including the endothelial-derived relaxing factor, NO, and
the vasoconstrictive factor, ET-I. It has been shown that the
NO and ET-I balance is involved in the pathogenesis of
intradialytic hypertension during HD.17 In our study, we also
found that the serum levels of NO were significantly
decreased in both groups, but the plasma levels of ET-1
were significant elevated only in group A. Thus, the NO/ET-1
balance was significantly depressed in group A compared
with that of group B, which may be the cause of the
inappropriate elevation of PVR seen in our study patients.
However, the possibility of production of other vasoconstric-
tions or removal of other vasodilators during HD still cannot
be excluded completely.
In this study, it was found that the hypertension-prone
HD patients had a lower reduction of percentage in BV. If the
ultrafiltration rate was similar, it meant that the refilling rate
of plasma was faster in hypertension-prone HD patients than
in the control group. During HD, water transfer between the
plasma and interstitium is driven by the combined
transvascular (capillary) oncotic and hydraulic pressure
gradients. Since in our study, there were no significant
differences in the serum levels of albumin (the main
contributor of oncotic pressure) between these two groups,
the difference in hydraulic pressure between interstitial and
capillary was thus an important determinant of the rate
of change of plasma volume. Usually, the rapid repletion of
intravascular volume implies higher hydraulic pressure of
interstitial and hypervolemia.18 Thus, these patients might
have clinically undetectable hypervolemia, which is also
Table 3 | Cardiac output and peripheral vascular resistance




CO (l/min) 6.470.9 5.470.3 NS
PVR (Wood units) 16.771.5 18.471.3 NS
After hemodialysis
CO (l/min) 5.470.8 4.870.3 NS
PVR (Wood units) 24.772.5** 20.671.7* NS
Change of CO in percentage (%) 18.275.2 12.575.2 NS
Change of PVR in percentage (%) 56.879.2 17.779.5 o0.05
Abbreviation: NS, not significant.
All data are presented as mean7s.e.m.
*Po0.05 when compared with values before hemodialysis, **Po0.005 when
compared with values before hemodialysis.
Table 4 | Plasma concentrations of nitric oxide (nitrate+ni-
trite) and endothelin (ET-1) before and after hemodialysis
Hypertension prone Control P-value
Before hemodialysis
NO (mM) 41.276.1 32.974.5 NS
ET-1 (pg/ml) 345.6734.5 287.4729.3 NS
NO/ET-1 0.86970.502 0.12970.013 NS
After hemodialysis
NO (mM) 7.270.9** 7.970.9** NS
ET-1 (pg/ml) 510.9743.3** 276.7730.1 o0.05
NO/ET-1 0.01870.003** 0.03470.005** o0.05
Abbreviations: NO, nitric oxide; ET-1, endothelin; NS, not significant.
All data are presented as mean7s.e.m.
*Po0.05 when compared with values before hemodialysis, **Po0.005 when
compared with values before hemodialysis.
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suggested by the higher basal blood pressure. In fact, many
factors have been proposed to be the cause of arterial
hypertension in HD patients.19 Hypervolemia is supposed to
be the most common factor.7,14 Is it the cause of intradialytic
hypertension, too? In the presence of intradialytic hyperten-
sion, an increase in ultrafiltration rate and reduction of dry
weight were the usual strategies that had been adopted and
were suggested to be effective.7,8 However, most patients
present with even higher blood pressure during HD after
increases in ultrafiltration rates. Factors other than hypervo-
lemia must participate in the pathogenesis of acute increase
of blood pressure during HD. If hypervolemia did not exist, is
it possible that the faster refilling rate of plasma in
hypertension-prone HD patients is initiated by the inap-
propriate elevation of PVR? And the arteriolar vasoconstric-
tion results in decreased mean intracapillary hydraulic
pressure that favors refilling of the plasma volume.12
Although inappropriate elevations of PVR seemed reasonable
to explain the faster refilling of plasma volume, the possibility
of some of these hypertension-prone HD patients also having
subclinic hypervolemia still cannot be excluded. In fact, it has
been proposed that the susceptibility to hypervolemia is
increased in the renal patients due to inappropriately elevated
activity of pressor systems (and/or decreased activity of
depressor systems), including abnormalities of ET-1 and NO.20
In addition to the factors mentioned above, disequili-
brium syndrome, hypokalemia, hypercalcemia, increased Hct
due to ultrafiltration, or removal of antihypertensive
medications have also been proposed to be responsible for
intradialytic hypertension.7,21 Nonetheless, according to
biochemical data before and after HD and discontinuation
of antihypertensive medications at least 2 weeks prior to
beginning our study, these factors are less likely to be the
major causes of intradialytic hypertension.
Another factor that may be involved is the stimulated
renin–angiotensin system due to dialysis-associated hypoka-
lemia and intravascular volume reduction.14 In this study,
both groups of patients showed similar serum concentration
of potassium not only at the beginning but also at the end of
HD. Besides, the conditions of HD, including the content of
dialysate, blood flow, and dialysate flow were similar.
Although on-line measurement of potassium was not
performed, it was reasonable to assume that the change of
serum levels of potassium were comparable. Although
Bazzato et al.22 reported effectively preventing intradialytic
hypertension by giving 50 mg of captopril before dialysis,
from the data of plasma renin concentrations in this study,
there were no significant increases in the activity of the
renin–angiotensin system in the hypertension-prone group.
This was also supported by the fact that there were no
responses to the 50 mg of captopril given at other HD
sessions in our hypertension-prone patients (data not
shown). Thus, the stimulated renin–angiotensin system due
to dialysis-associated hypokalemia and intravascular volume
reduction seems not to be the major cause of intradialytic
hypertension.
In conclusion, this study suggests that the physiological
changes of intradialysis hypertension patients were character-
ized by inappropriate elevation of PVR through mechanisms
that did not involve sympathetic stimulation or renin
activation but might be related with altered NO/ET-1 balance.
MATERIALS AND METHODS
Subjects
Patients were collected from a pool of 315 end-stage renal disease
patients on HD. The protocol was approved by the Human Research
Review Committee at the Kaohsiung Veterans General Hospital and
informed written consent was obtained from each patient. Two
groups of uremic patients on chronic HD therapy were studied.
Group A consisted of 30 dialysis-associated hypertensive patients
(patients who were normotensive or hypertensive at initiation of
dialysis, but who had experienced elevation in mean arterial blood
pressure of 15 mm Hg during more than two-thirds of the most
recent 12 treatment sessions). Group B consisted of 30 age, sex-
matched HD patients who had not experienced any hemodynamical
instability during their most recent 12 treatments. The underlying
diseases of renal failure for patients in group A were chronic
glomerulonephritis in 14 patients, chronic interstitial nephritis in
12, and unknown in four; in group B these were chronic interstitial
nephritis in 13 patients, chronic glomerulonephritis in 12, gouty
nephropathy in two and unknown in three.
Methods
All of the patients were treated three times a week for four hours
with diacetyl-cuprophan dialyzers of a 1.7 m2 surface area, blood
flow rates of 200–250 ml/min, and dialysate flow rates of 500 ml/
min. The dialysate composition was: Naþ , 140 mEq/l; Kþ , 2 mEq/l;
Ca2þ , 3.5 mEq/l; HCO3

, 35 mEq/l; and glucose, 200 mg/dl. The
dialysate temperature was maintained at 36.51C. Ultrafiltration rate
was held constant during the treatment. The dry weights of the
patients were set using clinical assessment and by trial and error.
Briefly, the dry weight was assessed on a regular basis in each dialysis
session. In the presence of hypertension, expanded extracellular
fluid, and high cardiothoracic ratio, on chest radiograph
(455–60%), dry weight was lowered gradually until the disappear-
ance of these manifestations and the occurrence of intradialytic
hypotension or muscle cramps. On the contrary, dry weight was
raised when intradialysis hypotension or muscle cramps developed
without significant interdialysis weight gain (45% body weight) or
other precipitating factors. Patients with diabetes mellitus, con-
gestive heart failure (more severe than NYHA Functional class II), or
medications that may affect the cardiovascular or autonomic
nervous system (including antihypertensive medications) were
excluded from the study, or the medications were discontinued
for 2 weeks prior to the study. All patients complied with the fluid
restriction recommendations and restricted their weight gain to less
than 1 kg per day and less than 5% of postdialysis dry weight
between two consecutive HD sessions. All procedures were
performed in the afternoon between 13:00 and 17:00 hours. Regular
HD was performed in a quiet room.
Plasma biochemistry and hormones assays
The serum potassium levels of each patient were checked before the
study. If the levels were not within the range of 4–5 mEq/l the study
was rescheduled. The blood urea nitrogen, plasma levels of
creatinine, sodium, potassium, chloride, free calcium, and Hct were
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checked at the beginning and the end of HD. To measure plasma
levels of epinephrine, norepinephrine, and renin, 10 ml of blood was
collected from the HD access after a 10-min rest in the supine
position before and at the end of HD. Blood samples were kept on
ice before separation in a refrigeration centrifuge at 41C, and then
stored at 701C until processing. Epinephrine and norepinephrine
plasma concentrations were determined with a Beckmann System
Gold high-performance liquid chromatograph (HPLC) and electro-
chemical detection (Chromsystems no. 41 000). A catecholamine-
detection kit (Chromsystems Catalog no. 5000) included a probe
preparation system, HPLC column, and all necessary chemicals and
buffers. The lower detection limit was 10 pg/ml for both epinephrine
and norepinephrine, with a coefficient of variation of 6.2% for
norepinephrine and 6.8% for epinephrine, respectively. All speci-
mens were assayed within 1 week after sampling. Active renin
concentration was determined in plasma using an immunoradio-
metric assay (Renin IRMA, Daiichi, Tokyo, Japan). The range of
assay was 5–500 pg/ml. The intra-assay variation was 1.4% and the
interassay variation 1.5%. Each sample was assayed in duplicate.
Nitric oxide and endothelin assays
To measure nitric oxide (NO) and ET-1, blood samples were
collected from the HD access after a 10-min rest in the supine
position before and at the end of HD. Blood samples (5 ml) were
centrifuged at 1000 g for 15 min. After centrifugation, serum was
aliquoted and stored at 701C until batch analysis. Measurements of
serum concentrations of total nitrites and nitrates were performed by
using an NO analyzer (Sievers 280, Boulder, CO, USA). Because there
is no evidence that the blood should contain any significant amounts
of nitrites and nitrates other than that contributed by NO, we can
assume that the NO concentration deduced from the chemilumines-
cence experiment does represent the true NO concentration in the
blood. The procedure is described briefly as follows. Serum samples
were deproteinized by zinc sulfate and the supernatants after
deproteinization were collected for further analysis.23 Assay of serum
nitrites and nitrates was then carried out according to the NO
analyzer manufacturer’s instructions. Vanadium (III) chloride was
used as the reducing agent in the system. A sodium nitrate (100 mM)
solution (NaNO3) was prepared and diluted to various concentra-
tions for the calibration test. Of a standard concentration, 10ml of
NaNO3 was injected into the Radical Purger, which was linked to the
NO analyzer, to obtain the calibration curve and the peak area for
each standard concentration was measured. Deproteinized serum
samples were then injected and the NO concentrations measured
after correction for background noise. The Intra-assay and interassay
coefficients of variation were 4.8 and 5.8%.
Plasma samples for ET-1 measurements were collected using
EDTA as an anticoagulant. Samples were immediately centrifuged at
3000 g for 10 min, and the plasma was stored at 701C until further
analysis. Endothelin was measured by immunoassay (R&D System
Inc., Minneapolis, MN, USA). The detection limit was 1 pg/ml for
ET-1. There was o1% crossreactivity with big ET-22 to 38. Intra-
assay and interassay coefficients of variation were 4.5 and 6.6%,
respectively. Results were expressed as pg/ml. Each sample was
assayed in duplicate.
Monitoring of hematocrit changes during hemodialysis
Hematocrit was continuously and noninvasively monitored during
each session using the Crit-Line instrument (In-Line Diagnostics,
Riverdale, UT, USA). Continuously monitored Hct has been
reported to have good correlation with Hct determined by
centrifugation (R¼ 0.89),24 and the differences of Hct could be
used to represent the relative changes of BV during HD.25,26 Before
HD, a sterile, plastic, disposable blood chamber (Beta prototype; In-
Line Diagnostics, Riverdale, UT, USA) was placed in the blood
circuit between the arterial blood tubing and the dialyzer. The Crit-
Line instrument uses a transmissive photometric technique to
determine the Hct based on both the absorption properties of
hemoglobin and the scattering properties of red blood cells passing
through the blood chamber. The percentage of BV changes was
calculated using an equation previously described.27
%BV change ¼ ½ðHctinitial=HctfinalÞ  1100%
Heart rate variability analysis and autonomic function
assessment
Blood pressure was checked 10 min before puncturing, at the
beginning of dialysis, every 15 min during HD, and at the end of HD,
using an automatic blood pressure device (Colin Press-Mate BP-
8800; Colin, Komaki City, Japan). We prepared a Holter ECG
recorder for all patients while receiving HD. The Holter ECG signal
was recorded for the entire duration of HD using an Oxford solid
state three-channel recorder (Medilogs Holter Recorder; Oxford
Instruments, Fremont, CA, USA). Using Microsoft Excel software
version 2.0 to detect the QRS complex, the signals were automatically
processed on the Oxford laser Holter scanner to perform HRV
analysis. Spectral analysis of HRV was performed every 5 min using
the Welch method on short-lasting heart rate tracers. Heart rate
variability analysis was carried out according to the recommenda-
tions of the task force of the European Society of Cardiology and the
North American Society of Pacing and Electrophysiology.28 Power
spectral analysis was performed by fast Fourier transformation for
the Holter ECG signals. Low frequency (0.04–0.15 Hz) represented
sympathetic activity, and HF (0.15–0.4 Hz) represented parasympa-
thetic activity. The ratio of LF/HF represented the balance between
sympathetic and parasympathetic activity.28–30
Systemic vascular resistances
Echocardiograms were performed before and at the end of HD using a
Sonos 5500 (HP, Agilent, Palo Alto, CA, USA) echocardiographic
system. M-mode measurements were obtained according to the
American Society of Echocardiography standards. We measured aortic
annulus dimension (Ao) and aortic Doppler velocity time integral
(AoVTI). The reproducibility (s.d./mean of three successive measure-
ments) of Ao and AoVTI measurement was 573 and 874%
(mean7s.d.). The blood pressure was measured twice by an
experienced nurse using arm cuff measurements of a sphygmonometer
(Baumanometers Kompak Model, Copiague, NY, USA) after at least
10 min of rest in a supine position in a quiet room immediately prior
to the echocardiograms. The reproducibility of systolic blood pressure
(SBP) and diastolic blood pressure (DBP) was 674 and 573%
(mean7s.d.). The SVR were determined using the following equations:
MBP ðmmHgÞ ¼ ðSBP þ 2DBPÞ
3
SV ðmlÞ ¼ AoVTIpAo
2
4
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Statistical analysis
All data are expressed as mean7s.e.m. To analyze the data, we
applied unpaired t-tests to test the differences between the groups,
and repeated measurements of analysis of variance (ANOVA) to
examine the differences among serial measurements within the
groups. The Student–Neuman–Keuls test was used for pairwise
comparisons among serial measurements. Data before and after HD
were analyzed using paired t-tests. All P-levels were two-tailed, and
values of less than 0.05 were considered significant. Statistical
analyses were conducted using SPSS 8.0.1C (SPSS Inc., Chicago, IL,
USA).
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